▶Kleiner Perkins has a strong founder-centric philosophy, believing that replacing founder CEOs leads to poor outcomes and observing that its top portfolio companies promote from within rather than hiring external executives (claims 6, 11, 21).Jun–Jul 2026

▶The firm provides significant hands-on support beyond capital, including incubating companies like Glean and Roadrunner and operating a portfolio operations team focused on go-to-market support for technical founders (claims 17, 18, 19, 29).

▶Kleiner Perkins is an active investor in the AI sector, with portfolio companies including Poetic, Synthesia, Ambience, Codium (Windsurf), and Browserbase (claims 1, 13, 22, 30, 33).Jun–Jul 2026

▶The firm operates multiple large funds simultaneously, including a recently raised $1 billion early-stage fund, a $2.5 billion growth fund, an $800 million venture fund (KP21), and a $1.2 billion growth fund named Select (claims 5, 27, 28).Jun–Jul 2026

▶The firm's AI investment strategy appears selective and has evolved; they passed on Synthesia's early rounds viewing it as a 'toy' and later passed on OpenAI's $32 billion round due to structural concerns, yet they also invested in Synthesia's Series B in 2021 before the AI hype cycle (claims 12, 13, 37).

▶There is a contrast between the historical power dynamic of venture capital and the present reality. In the past, firms like Kleiner Perkins could invest small amounts for large stakes (e.g., $3M for 30%), whereas now they must invest much larger sums for smaller stakes (e.g., $50M for 3%) to win competitive deals (claim 35).Jun–Jul 2026

▶The firm's investment criteria can be misperceived from the outside. For example, partner Mary Meeker, known publicly as a quantitative investor, was described internally by a colleague as the most qualitative investor he had ever worked with (claim 38).

▶While the firm actively incubates companies like Roadrunner and Glean, this is not a frequent activity, with Roadrunner being the first such effort since Glean in 2019, suggesting a selective and opportunistic approach to incubation rather than a core, continuous strategy (claim 18).